nodes	percent_of_prediction	percent_of_DWPC	metapath
Domperidone—CYP2C8—Tazarotene—psoriasis	0.0625	0.075	CbGbCtD
Domperidone—CYP3A5—Beclomethasone—psoriasis	0.0604	0.0725	CbGbCtD
Domperidone—CYP1A2—Clobetasol propionate—psoriasis	0.0593	0.0712	CbGbCtD
Domperidone—CYP2B6—Cholecalciferol—psoriasis	0.0352	0.0422	CbGbCtD
Domperidone—CYP1A2—Methoxsalen—psoriasis	0.0312	0.0374	CbGbCtD
Domperidone—CYP2D6—Hydroxyurea—psoriasis	0.0281	0.0337	CbGbCtD
Domperidone—CYP2C8—Cholecalciferol—psoriasis	0.0267	0.032	CbGbCtD
Domperidone—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0257	0.0309	CbGbCtD
Domperidone—CYP3A7—Hydrocortisone—psoriasis	0.0257	0.0309	CbGbCtD
Domperidone—CYP3A7—Cyclosporine—psoriasis	0.0243	0.0291	CbGbCtD
Domperidone—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0243	0.0291	CbGbCtD
Domperidone—CYP3A5—Mycophenolate mofetil—psoriasis	0.024	0.0289	CbGbCtD
Domperidone—CYP2C8—Mycophenolate mofetil—psoriasis	0.0231	0.0277	CbGbCtD
Domperidone—CYP3A4—Calcitriol—psoriasis	0.021	0.0252	CbGbCtD
Domperidone—CYP3A5—Hydrocortisone—psoriasis	0.0193	0.0232	CbGbCtD
Domperidone—CYP2C8—Hydrocortisone—psoriasis	0.0186	0.0223	CbGbCtD
Domperidone—CYP3A5—Cyclosporine—psoriasis	0.0182	0.0219	CbGbCtD
Domperidone—CYP2C8—Cyclosporine—psoriasis	0.0175	0.021	CbGbCtD
Domperidone—CYP2D6—Cholecalciferol—psoriasis	0.017	0.0204	CbGbCtD
Domperidone—CYP3A4—Methoxsalen—psoriasis	0.0163	0.0196	CbGbCtD
Domperidone—CYP3A7—Dexamethasone—psoriasis	0.016	0.0192	CbGbCtD
Domperidone—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.016	0.0192	CbGbCtD
Domperidone—ABCB1—Mycophenolate mofetil—psoriasis	0.0156	0.0188	CbGbCtD
Domperidone—CYP2B6—Dexamethasone—psoriasis	0.0152	0.0183	CbGbCtD
Domperidone—ABCB1—Betamethasone—psoriasis	0.0134	0.0161	CbGbCtD
Domperidone—ABCB1—Prednisolone—psoriasis	0.0132	0.0159	CbGbCtD
Domperidone—ABCB1—Hydrocortisone—psoriasis	0.0126	0.0151	CbGbCtD
Domperidone—ABCB1—Prednisone—psoriasis	0.0125	0.015	CbGbCtD
Domperidone—CYP3A5—Dexamethasone—psoriasis	0.012	0.0144	CbGbCtD
Domperidone—ABCB1—Cyclosporine—psoriasis	0.0119	0.0142	CbGbCtD
Domperidone—CYP2C8—Dexamethasone—psoriasis	0.0115	0.0138	CbGbCtD
Domperidone—CYP2D6—Cyclosporine—psoriasis	0.0112	0.0134	CbGbCtD
Domperidone—CYP3A4—Cholecalciferol—psoriasis	0.0108	0.013	CbGbCtD
Domperidone—CYP3A4—Triamcinolone—psoriasis	0.00938	0.0113	CbGbCtD
Domperidone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00938	0.0113	CbGbCtD
Domperidone—CYP3A4—Betamethasone—psoriasis	0.00804	0.00965	CbGbCtD
Domperidone—CYP3A4—Prednisolone—psoriasis	0.00794	0.00952	CbGbCtD
Domperidone—ABCB1—Dexamethasone—psoriasis	0.00781	0.00937	CbGbCtD
Domperidone—CYP3A4—Hydrocortisone—psoriasis	0.00752	0.00903	CbGbCtD
Domperidone—CYP3A4—Prednisone—psoriasis	0.00749	0.00899	CbGbCtD
Domperidone—CYP2D6—Dexamethasone—psoriasis	0.00736	0.00883	CbGbCtD
Domperidone—CYP3A4—Cyclosporine—psoriasis	0.00711	0.00853	CbGbCtD
Domperidone—ABCB1—Methotrexate—psoriasis	0.00628	0.00753	CbGbCtD
Domperidone—CYP3A4—Dexamethasone—psoriasis	0.00468	0.00561	CbGbCtD
Domperidone—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00179	0.0551	CbGpPWpGaD
Domperidone—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00151	0.0466	CbGpPWpGaD
Domperidone—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.0015	0.0462	CbGpPWpGaD
Domperidone—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00124	0.0383	CbGpPWpGaD
Domperidone—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00116	0.0357	CbGpPWpGaD
Domperidone—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00111	0.0341	CbGpPWpGaD
Domperidone—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00108	0.0334	CbGpPWpGaD
Domperidone—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000937	0.0289	CbGpPWpGaD
Domperidone—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000769	0.0237	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—IL22—psoriasis	0.000655	0.0202	CbGpPWpGaD
Domperidone—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000652	0.0201	CbGpPWpGaD
Domperidone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000621	0.0192	CbGpPWpGaD
Domperidone—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000613	0.0189	CbGpPWpGaD
Domperidone—Lethargy—Hydrocortisone—psoriasis	0.000531	0.00395	CcSEcCtD
Domperidone—Constipation—Calcitriol—psoriasis	0.00052	0.00387	CcSEcCtD
Domperidone—Nausea—Beclomethasone—psoriasis	0.000518	0.00386	CcSEcCtD
Domperidone—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000504	0.0155	CbGpPWpGaD
Domperidone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000503	0.0155	CbGpPWpGaD
Domperidone—Irritability—Hydrocortisone—psoriasis	0.000496	0.0037	CcSEcCtD
Domperidone—Insomnia—Acitretin—psoriasis	0.000489	0.00364	CcSEcCtD
Domperidone—Urticaria—Calcitriol—psoriasis	0.000483	0.00359	CcSEcCtD
Domperidone—Pruritus—Methoxsalen—psoriasis	0.000482	0.00359	CcSEcCtD
Domperidone—Somnolence—Acitretin—psoriasis	0.000481	0.00358	CcSEcCtD
Domperidone—Abdominal pain—Calcitriol—psoriasis	0.00048	0.00358	CcSEcCtD
Domperidone—Dyspepsia—Acitretin—psoriasis	0.000476	0.00354	CcSEcCtD
Domperidone—Dysuria—Cyclosporine—psoriasis	0.000473	0.00352	CcSEcCtD
Domperidone—Pollakiuria—Cyclosporine—psoriasis	0.000467	0.00348	CcSEcCtD
Domperidone—Constipation—Acitretin—psoriasis	0.000462	0.00344	CcSEcCtD
Domperidone—Dysuria—Mycophenolate mofetil—psoriasis	0.000461	0.00343	CcSEcCtD
Domperidone—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000459	0.0142	CbGpPWpGaD
Domperidone—Pollakiuria—Mycophenolate mofetil—psoriasis	0.000456	0.00339	CcSEcCtD
Domperidone—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000453	0.014	CbGpPWpGaD
Domperidone—Lethargy—Betamethasone—psoriasis	0.000453	0.00338	CcSEcCtD
Domperidone—Lethargy—Dexamethasone—psoriasis	0.000453	0.00338	CcSEcCtD
Domperidone—Dizziness—Methoxsalen—psoriasis	0.000451	0.00336	CcSEcCtD
Domperidone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000449	0.0139	CbGpPWpGaD
Domperidone—Arrhythmia—Mycophenolic acid—psoriasis	0.000447	0.00333	CcSEcCtD
Domperidone—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000443	0.0137	CbGpPWpGaD
Domperidone—Stomatitis—Cyclosporine—psoriasis	0.00044	0.00327	CcSEcCtD
Domperidone—Conjunctivitis—Cyclosporine—psoriasis	0.000438	0.00326	CcSEcCtD
Domperidone—Migraine—Dexamethasone—psoriasis	0.000437	0.00326	CcSEcCtD
Domperidone—Migraine—Betamethasone—psoriasis	0.000437	0.00326	CcSEcCtD
Domperidone—Asthenia—Calcitriol—psoriasis	0.000436	0.00325	CcSEcCtD
Domperidone—Pruritus—Calcitriol—psoriasis	0.00043	0.0032	CcSEcCtD
Domperidone—Rash—Methoxsalen—psoriasis	0.00043	0.0032	CcSEcCtD
Domperidone—Dermatitis—Methoxsalen—psoriasis	0.000429	0.0032	CcSEcCtD
Domperidone—Urticaria—Acitretin—psoriasis	0.000429	0.0032	CcSEcCtD
Domperidone—Stomatitis—Mycophenolate mofetil—psoriasis	0.000429	0.00319	CcSEcCtD
Domperidone—Conjunctivitis—Mycophenolate mofetil—psoriasis	0.000428	0.00318	CcSEcCtD
Domperidone—Tension—Mycophenolic acid—psoriasis	0.000427	0.00318	CcSEcCtD
Domperidone—Abdominal pain—Acitretin—psoriasis	0.000427	0.00318	CcSEcCtD
Domperidone—Headache—Methoxsalen—psoriasis	0.000427	0.00318	CcSEcCtD
Domperidone—Oedema—Hydroxyurea—psoriasis	0.000424	0.00316	CcSEcCtD
Domperidone—Irritability—Dexamethasone—psoriasis	0.000424	0.00316	CcSEcCtD
Domperidone—Irritability—Betamethasone—psoriasis	0.000424	0.00316	CcSEcCtD
Domperidone—Nervousness—Mycophenolic acid—psoriasis	0.000423	0.00315	CcSEcCtD
Domperidone—Muscle spasms—Mycophenolic acid—psoriasis	0.000419	0.00312	CcSEcCtD
Domperidone—Diarrhoea—Calcitriol—psoriasis	0.000416	0.0031	CcSEcCtD
Domperidone—Nausea—Methoxsalen—psoriasis	0.000405	0.00302	CcSEcCtD
Domperidone—Conjunctivitis—Prednisolone—psoriasis	0.000399	0.00297	CcSEcCtD
Domperidone—Gynaecomastia—Methotrexate—psoriasis	0.000399	0.00297	CcSEcCtD
Domperidone—Lethargy—Prednisone—psoriasis	0.000395	0.00294	CcSEcCtD
Domperidone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000389	0.012	CbGpPWpGaD
Domperidone—Asthenia—Acitretin—psoriasis	0.000388	0.00289	CcSEcCtD
Domperidone—Vomiting—Calcitriol—psoriasis	0.000386	0.00288	CcSEcCtD
Domperidone—Palpitations—Mycophenolic acid—psoriasis	0.000385	0.00287	CcSEcCtD
Domperidone—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000384	0.0118	CbGpPWpGaD
Domperidone—Rash—Calcitriol—psoriasis	0.000383	0.00285	CcSEcCtD
Domperidone—Dermatitis—Calcitriol—psoriasis	0.000383	0.00285	CcSEcCtD
Domperidone—Pruritus—Acitretin—psoriasis	0.000382	0.00285	CcSEcCtD
Domperidone—Pruritus—Fluocinolone Acetonide—psoriasis	0.000381	0.00284	CcSEcCtD
Domperidone—Headache—Calcitriol—psoriasis	0.000381	0.00283	CcSEcCtD
Domperidone—Somnolence—Hydroxyurea—psoriasis	0.000377	0.00281	CcSEcCtD
Domperidone—Dyspepsia—Hydroxyurea—psoriasis	0.000374	0.00278	CcSEcCtD
Domperidone—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000372	0.0115	CbGpPWpGaD
Domperidone—Diarrhoea—Acitretin—psoriasis	0.00037	0.00275	CcSEcCtD
Domperidone—Irritability—Prednisone—psoriasis	0.000369	0.00275	CcSEcCtD
Domperidone—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000369	0.00275	CcSEcCtD
Domperidone—Conjunctivitis—Triamcinolone—psoriasis	0.000367	0.00273	CcSEcCtD
Domperidone—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000364	0.0112	CbGpPWpGaD
Domperidone—Constipation—Hydroxyurea—psoriasis	0.000363	0.0027	CcSEcCtD
Domperidone—Dry mouth—Mycophenolic acid—psoriasis	0.000363	0.0027	CcSEcCtD
Domperidone—Arrhythmia—Cyclosporine—psoriasis	0.000362	0.00269	CcSEcCtD
Domperidone—Nausea—Calcitriol—psoriasis	0.000361	0.00269	CcSEcCtD
Domperidone—Dizziness—Acitretin—psoriasis	0.000357	0.00266	CcSEcCtD
Domperidone—Dizziness—Fluocinolone Acetonide—psoriasis	0.000356	0.00265	CcSEcCtD
Domperidone—Oedema—Mycophenolic acid—psoriasis	0.000355	0.00265	CcSEcCtD
Domperidone—Arrhythmia—Mycophenolate mofetil—psoriasis	0.000353	0.00263	CcSEcCtD
Domperidone—Tension—Cyclosporine—psoriasis	0.000346	0.00257	CcSEcCtD
Domperidone—Vomiting—Acitretin—psoriasis	0.000344	0.00256	CcSEcCtD
Domperidone—Vomiting—Fluocinolone Acetonide—psoriasis	0.000343	0.00255	CcSEcCtD
Domperidone—Nervousness—Cyclosporine—psoriasis	0.000342	0.00255	CcSEcCtD
Domperidone—Rash—Acitretin—psoriasis	0.000341	0.00254	CcSEcCtD
Domperidone—Dermatitis—Acitretin—psoriasis	0.000341	0.00254	CcSEcCtD
Domperidone—Rash—Fluocinolone Acetonide—psoriasis	0.00034	0.00253	CcSEcCtD
Domperidone—Dermatitis—Fluocinolone Acetonide—psoriasis	0.00034	0.00253	CcSEcCtD
Domperidone—Muscle spasms—Cyclosporine—psoriasis	0.000339	0.00252	CcSEcCtD
Domperidone—Headache—Acitretin—psoriasis	0.000339	0.00252	CcSEcCtD
Domperidone—Headache—Fluocinolone Acetonide—psoriasis	0.000338	0.00251	CcSEcCtD
Domperidone—Tension—Mycophenolate mofetil—psoriasis	0.000337	0.00251	CcSEcCtD
Domperidone—Nervousness—Mycophenolate mofetil—psoriasis	0.000334	0.00249	CcSEcCtD
Domperidone—Conjunctivitis—Dexamethasone—psoriasis	0.000333	0.00248	CcSEcCtD
Domperidone—Conjunctivitis—Betamethasone—psoriasis	0.000333	0.00248	CcSEcCtD
Domperidone—Hypotension—Mycophenolic acid—psoriasis	0.000332	0.00247	CcSEcCtD
Domperidone—Muscle spasms—Mycophenolate mofetil—psoriasis	0.00033	0.00246	CcSEcCtD
Domperidone—Lethargy—Methotrexate—psoriasis	0.00033	0.00246	CcSEcCtD
Domperidone—Arrhythmia—Prednisolone—psoriasis	0.000329	0.00245	CcSEcCtD
Domperidone—Insomnia—Mycophenolic acid—psoriasis	0.000322	0.00239	CcSEcCtD
Domperidone—Arrhythmia—Hydrocortisone—psoriasis	0.000321	0.00239	CcSEcCtD
Domperidone—Nausea—Acitretin—psoriasis	0.000321	0.00239	CcSEcCtD
Domperidone—Nausea—Fluocinolone Acetonide—psoriasis	0.00032	0.00238	CcSEcCtD
Domperidone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000319	0.00986	CbGpPWpGaD
Domperidone—Somnolence—Mycophenolic acid—psoriasis	0.000316	0.00235	CcSEcCtD
Domperidone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000315	0.00973	CbGpPWpGaD
Domperidone—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000315	0.00973	CbGpPWpGaD
Domperidone—Dyspepsia—Mycophenolic acid—psoriasis	0.000313	0.00233	CcSEcCtD
Domperidone—Irritability—Methotrexate—psoriasis	0.000309	0.0023	CcSEcCtD
Domperidone—Asthenia—Hydroxyurea—psoriasis	0.000305	0.00227	CcSEcCtD
Domperidone—Constipation—Mycophenolic acid—psoriasis	0.000304	0.00226	CcSEcCtD
Domperidone—Palpitations—Mycophenolate mofetil—psoriasis	0.000304	0.00226	CcSEcCtD
Domperidone—Arrhythmia—Triamcinolone—psoriasis	0.000303	0.00225	CcSEcCtD
Domperidone—Dry mouth—Cyclosporine—psoriasis	0.000293	0.00218	CcSEcCtD
Domperidone—Diarrhoea—Hydroxyurea—psoriasis	0.00029	0.00216	CcSEcCtD
Domperidone—Oedema—Cyclosporine—psoriasis	0.000288	0.00214	CcSEcCtD
Domperidone—Dry mouth—Mycophenolate mofetil—psoriasis	0.000286	0.00213	CcSEcCtD
Domperidone—Abdominal pain—Mycophenolic acid—psoriasis	0.000281	0.00209	CcSEcCtD
Domperidone—Dizziness—Hydroxyurea—psoriasis	0.000281	0.00209	CcSEcCtD
Domperidone—Oedema—Mycophenolate mofetil—psoriasis	0.000281	0.00209	CcSEcCtD
Domperidone—Arrhythmia—Betamethasone—psoriasis	0.000275	0.00204	CcSEcCtD
Domperidone—Arrhythmia—Dexamethasone—psoriasis	0.000275	0.00204	CcSEcCtD
Domperidone—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000271	0.00836	CbGpPWpGaD
Domperidone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000271	0.00835	CbGpPWpGaD
Domperidone—Vomiting—Hydroxyurea—psoriasis	0.00027	0.00201	CcSEcCtD
Domperidone—Rash—Hydroxyurea—psoriasis	0.000268	0.00199	CcSEcCtD
Domperidone—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000268	0.00826	CbGpPWpGaD
Domperidone—Dermatitis—Hydroxyurea—psoriasis	0.000267	0.00199	CcSEcCtD
Domperidone—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000267	0.00824	CbGpPWpGaD
Domperidone—Headache—Hydroxyurea—psoriasis	0.000266	0.00198	CcSEcCtD
Domperidone—KCNH2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000266	0.0082	CbGpPWpGaD
Domperidone—DRD3—G alpha (i) signalling events—HCAR2—psoriasis	0.000265	0.00819	CbGpPWpGaD
Domperidone—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000264	0.00814	CbGpPWpGaD
Domperidone—Hypotension—Mycophenolate mofetil—psoriasis	0.000262	0.00195	CcSEcCtD
Domperidone—Oedema—Prednisolone—psoriasis	0.000262	0.00195	CcSEcCtD
Domperidone—Dysuria—Methotrexate—psoriasis	0.000261	0.00195	CcSEcCtD
Domperidone—Insomnia—Cyclosporine—psoriasis	0.00026	0.00194	CcSEcCtD
Domperidone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000259	0.00799	CbGpPWpGaD
Domperidone—Somnolence—Cyclosporine—psoriasis	0.000256	0.0019	CcSEcCtD
Domperidone—Oedema—Hydrocortisone—psoriasis	0.000256	0.0019	CcSEcCtD
Domperidone—Asthenia—Mycophenolic acid—psoriasis	0.000255	0.0019	CcSEcCtD
Domperidone—Insomnia—Mycophenolate mofetil—psoriasis	0.000254	0.00189	CcSEcCtD
Domperidone—Dyspepsia—Cyclosporine—psoriasis	0.000253	0.00188	CcSEcCtD
Domperidone—Nausea—Hydroxyurea—psoriasis	0.000252	0.00188	CcSEcCtD
Domperidone—Pruritus—Mycophenolic acid—psoriasis	0.000251	0.00187	CcSEcCtD
Domperidone—Somnolence—Mycophenolate mofetil—psoriasis	0.000249	0.00186	CcSEcCtD
Domperidone—Drowsiness—Methotrexate—psoriasis	0.000249	0.00186	CcSEcCtD
Domperidone—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000247	0.00184	CcSEcCtD
Domperidone—Constipation—Cyclosporine—psoriasis	0.000246	0.00183	CcSEcCtD
Domperidone—Dry mouth—Triamcinolone—psoriasis	0.000246	0.00183	CcSEcCtD
Domperidone—Diarrhoea—Mycophenolic acid—psoriasis	0.000243	0.00181	CcSEcCtD
Domperidone—Stomatitis—Methotrexate—psoriasis	0.000243	0.00181	CcSEcCtD
Domperidone—Conjunctivitis—Methotrexate—psoriasis	0.000242	0.0018	CcSEcCtD
Domperidone—Oedema—Triamcinolone—psoriasis	0.000241	0.00179	CcSEcCtD
Domperidone—Constipation—Mycophenolate mofetil—psoriasis	0.00024	0.00179	CcSEcCtD
Domperidone—Arrhythmia—Prednisone—psoriasis	0.000239	0.00178	CcSEcCtD
Domperidone—Hypotension—Hydrocortisone—psoriasis	0.000239	0.00178	CcSEcCtD
Domperidone—Insomnia—Prednisolone—psoriasis	0.000237	0.00176	CcSEcCtD
Domperidone—Dizziness—Mycophenolic acid—psoriasis	0.000235	0.00175	CcSEcCtD
Domperidone—Insomnia—Hydrocortisone—psoriasis	0.000231	0.00172	CcSEcCtD
Domperidone—Urticaria—Cyclosporine—psoriasis	0.000228	0.0017	CcSEcCtD
Domperidone—Abdominal pain—Cyclosporine—psoriasis	0.000227	0.00169	CcSEcCtD
Domperidone—Vomiting—Mycophenolic acid—psoriasis	0.000226	0.00168	CcSEcCtD
Domperidone—Dyspepsia—Hydrocortisone—psoriasis	0.000225	0.00167	CcSEcCtD
Domperidone—Rash—Mycophenolic acid—psoriasis	0.000224	0.00167	CcSEcCtD
Domperidone—Dermatitis—Mycophenolic acid—psoriasis	0.000224	0.00167	CcSEcCtD
Domperidone—Urticaria—Mycophenolate mofetil—psoriasis	0.000223	0.00166	CcSEcCtD
Domperidone—Headache—Mycophenolic acid—psoriasis	0.000223	0.00166	CcSEcCtD
Domperidone—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000222	0.00165	CcSEcCtD
Domperidone—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000219	0.00677	CbGpPWpGaD
Domperidone—Oedema—Dexamethasone—psoriasis	0.000218	0.00163	CcSEcCtD
Domperidone—Oedema—Betamethasone—psoriasis	0.000218	0.00163	CcSEcCtD
Domperidone—Insomnia—Triamcinolone—psoriasis	0.000218	0.00162	CcSEcCtD
Domperidone—Dyspepsia—Triamcinolone—psoriasis	0.000212	0.00158	CcSEcCtD
Domperidone—Nausea—Mycophenolic acid—psoriasis	0.000211	0.00157	CcSEcCtD
Domperidone—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000211	0.00651	CbGpPWpGaD
Domperidone—DRD3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000211	0.00651	CbGpPWpGaD
Domperidone—KCNH2—SIDS Susceptibility Pathways—IL13—psoriasis	0.00021	0.00648	CbGpPWpGaD
Domperidone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000209	0.00644	CbGpPWpGaD
Domperidone—Urticaria—Prednisolone—psoriasis	0.000208	0.00155	CcSEcCtD
Domperidone—Asthenia—Cyclosporine—psoriasis	0.000206	0.00154	CcSEcCtD
Domperidone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000206	0.00636	CbGpPWpGaD
Domperidone—Hypotension—Betamethasone—psoriasis	0.000204	0.00152	CcSEcCtD
Domperidone—Hypotension—Dexamethasone—psoriasis	0.000204	0.00152	CcSEcCtD
Domperidone—Pruritus—Cyclosporine—psoriasis	0.000203	0.00151	CcSEcCtD
Domperidone—DRD2—G alpha (i) signalling events—HCAR2—psoriasis	0.000203	0.00627	CbGpPWpGaD
Domperidone—Urticaria—Hydrocortisone—psoriasis	0.000203	0.00151	CcSEcCtD
Domperidone—Abdominal pain—Hydrocortisone—psoriasis	0.000202	0.0015	CcSEcCtD
Domperidone—Asthenia—Mycophenolate mofetil—psoriasis	0.000201	0.0015	CcSEcCtD
Domperidone—Pruritus—Mycophenolate mofetil—psoriasis	0.000198	0.00148	CcSEcCtD
Domperidone—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000198	0.00611	CbGpPWpGaD
Domperidone—Insomnia—Dexamethasone—psoriasis	0.000197	0.00147	CcSEcCtD
Domperidone—Insomnia—Betamethasone—psoriasis	0.000197	0.00147	CcSEcCtD
Domperidone—Diarrhoea—Cyclosporine—psoriasis	0.000197	0.00146	CcSEcCtD
Domperidone—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000195	0.00602	CbGpPWpGaD
Domperidone—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000193	0.00597	CbGpPWpGaD
Domperidone—Dyspepsia—Betamethasone—psoriasis	0.000192	0.00143	CcSEcCtD
Domperidone—Dyspepsia—Dexamethasone—psoriasis	0.000192	0.00143	CcSEcCtD
Domperidone—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000192	0.00143	CcSEcCtD
Domperidone—Urticaria—Triamcinolone—psoriasis	0.000191	0.00142	CcSEcCtD
Domperidone—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000191	0.00589	CbGpPWpGaD
Domperidone—Dizziness—Cyclosporine—psoriasis	0.00019	0.00142	CcSEcCtD
Domperidone—Oedema—Prednisone—psoriasis	0.00019	0.00142	CcSEcCtD
Domperidone—Dizziness—Mycophenolate mofetil—psoriasis	0.000186	0.00138	CcSEcCtD
Domperidone—Asthenia—Hydrocortisone—psoriasis	0.000183	0.00137	CcSEcCtD
Domperidone—Vomiting—Cyclosporine—psoriasis	0.000183	0.00136	CcSEcCtD
Domperidone—Rash—Cyclosporine—psoriasis	0.000181	0.00135	CcSEcCtD
Domperidone—Dermatitis—Cyclosporine—psoriasis	0.000181	0.00135	CcSEcCtD
Domperidone—Pruritus—Hydrocortisone—psoriasis	0.000181	0.00135	CcSEcCtD
Domperidone—Headache—Cyclosporine—psoriasis	0.00018	0.00134	CcSEcCtD
Domperidone—Vomiting—Mycophenolate mofetil—psoriasis	0.000178	0.00133	CcSEcCtD
Domperidone—Rash—Mycophenolate mofetil—psoriasis	0.000177	0.00132	CcSEcCtD
Domperidone—Dermatitis—Mycophenolate mofetil—psoriasis	0.000177	0.00132	CcSEcCtD
Domperidone—Headache—Mycophenolate mofetil—psoriasis	0.000176	0.00131	CcSEcCtD
Domperidone—Diarrhoea—Hydrocortisone—psoriasis	0.000175	0.0013	CcSEcCtD
Domperidone—Urticaria—Betamethasone—psoriasis	0.000173	0.00129	CcSEcCtD
Domperidone—Urticaria—Dexamethasone—psoriasis	0.000173	0.00129	CcSEcCtD
Domperidone—Dizziness—Prednisolone—psoriasis	0.000173	0.00129	CcSEcCtD
Domperidone—Asthenia—Triamcinolone—psoriasis	0.000173	0.00129	CcSEcCtD
Domperidone—Abdominal pain—Betamethasone—psoriasis	0.000173	0.00129	CcSEcCtD
Domperidone—Abdominal pain—Dexamethasone—psoriasis	0.000173	0.00129	CcSEcCtD
Domperidone—Insomnia—Prednisone—psoriasis	0.000172	0.00128	CcSEcCtD
Domperidone—Nausea—Cyclosporine—psoriasis	0.000171	0.00127	CcSEcCtD
Domperidone—Pruritus—Triamcinolone—psoriasis	0.00017	0.00127	CcSEcCtD
Domperidone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000169	0.00522	CbGpPWpGaD
Domperidone—Dizziness—Hydrocortisone—psoriasis	0.000169	0.00126	CcSEcCtD
Domperidone—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000168	0.00517	CbGpPWpGaD
Domperidone—Dyspepsia—Prednisone—psoriasis	0.000167	0.00125	CcSEcCtD
Domperidone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000167	0.00515	CbGpPWpGaD
Domperidone—Nausea—Mycophenolate mofetil—psoriasis	0.000167	0.00124	CcSEcCtD
Domperidone—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000165	0.0051	CbGpPWpGaD
Domperidone—Rash—Prednisolone—psoriasis	0.000165	0.00123	CcSEcCtD
Domperidone—Dermatitis—Prednisolone—psoriasis	0.000165	0.00123	CcSEcCtD
Domperidone—Headache—Prednisolone—psoriasis	0.000164	0.00122	CcSEcCtD
Domperidone—Constipation—Prednisone—psoriasis	0.000163	0.00121	CcSEcCtD
Domperidone—Vomiting—Hydrocortisone—psoriasis	0.000162	0.00121	CcSEcCtD
Domperidone—DRD2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000161	0.00498	CbGpPWpGaD
Domperidone—Rash—Hydrocortisone—psoriasis	0.000161	0.0012	CcSEcCtD
Domperidone—Dermatitis—Hydrocortisone—psoriasis	0.000161	0.0012	CcSEcCtD
Domperidone—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000161	0.00496	CbGpPWpGaD
Domperidone—DRD3—GPCR ligand binding—HCAR2—psoriasis	0.000161	0.00496	CbGpPWpGaD
Domperidone—Headache—Hydrocortisone—psoriasis	0.00016	0.00119	CcSEcCtD
Domperidone—Dizziness—Triamcinolone—psoriasis	0.000159	0.00118	CcSEcCtD
Domperidone—Asthenia—Betamethasone—psoriasis	0.000157	0.00117	CcSEcCtD
Domperidone—Asthenia—Dexamethasone—psoriasis	0.000157	0.00117	CcSEcCtD
Domperidone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000156	0.0048	CbGpPWpGaD
Domperidone—Nausea—Prednisolone—psoriasis	0.000155	0.00116	CcSEcCtD
Domperidone—Pruritus—Dexamethasone—psoriasis	0.000154	0.00115	CcSEcCtD
Domperidone—Pruritus—Betamethasone—psoriasis	0.000154	0.00115	CcSEcCtD
Domperidone—Vomiting—Triamcinolone—psoriasis	0.000153	0.00114	CcSEcCtD
Domperidone—Nausea—Hydrocortisone—psoriasis	0.000152	0.00113	CcSEcCtD
Domperidone—Rash—Triamcinolone—psoriasis	0.000152	0.00113	CcSEcCtD
Domperidone—Dermatitis—Triamcinolone—psoriasis	0.000152	0.00113	CcSEcCtD
Domperidone—Urticaria—Prednisone—psoriasis	0.000151	0.00112	CcSEcCtD
Domperidone—Headache—Triamcinolone—psoriasis	0.000151	0.00112	CcSEcCtD
Domperidone—Abdominal pain—Prednisone—psoriasis	0.00015	0.00112	CcSEcCtD
Domperidone—Diarrhoea—Betamethasone—psoriasis	0.000149	0.00111	CcSEcCtD
Domperidone—Diarrhoea—Dexamethasone—psoriasis	0.000149	0.00111	CcSEcCtD
Domperidone—Hypotension—Methotrexate—psoriasis	0.000149	0.00111	CcSEcCtD
Domperidone—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000147	0.00454	CbGpPWpGaD
Domperidone—Dizziness—Dexamethasone—psoriasis	0.000144	0.00108	CcSEcCtD
Domperidone—Dizziness—Betamethasone—psoriasis	0.000144	0.00108	CcSEcCtD
Domperidone—Insomnia—Methotrexate—psoriasis	0.000144	0.00107	CcSEcCtD
Domperidone—Nausea—Triamcinolone—psoriasis	0.000143	0.00106	CcSEcCtD
Domperidone—Somnolence—Methotrexate—psoriasis	0.000141	0.00105	CcSEcCtD
Domperidone—Dyspepsia—Methotrexate—psoriasis	0.00014	0.00104	CcSEcCtD
Domperidone—Vomiting—Betamethasone—psoriasis	0.000139	0.00103	CcSEcCtD
Domperidone—Vomiting—Dexamethasone—psoriasis	0.000139	0.00103	CcSEcCtD
Domperidone—DRD3—G alpha (i) signalling events—CCL20—psoriasis	0.000138	0.00425	CbGpPWpGaD
Domperidone—Rash—Betamethasone—psoriasis	0.000138	0.00103	CcSEcCtD
Domperidone—Rash—Dexamethasone—psoriasis	0.000138	0.00103	CcSEcCtD
Domperidone—Dermatitis—Dexamethasone—psoriasis	0.000138	0.00102	CcSEcCtD
Domperidone—Dermatitis—Betamethasone—psoriasis	0.000138	0.00102	CcSEcCtD
Domperidone—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000138	0.00424	CbGpPWpGaD
Domperidone—Headache—Dexamethasone—psoriasis	0.000137	0.00102	CcSEcCtD
Domperidone—Headache—Betamethasone—psoriasis	0.000137	0.00102	CcSEcCtD
Domperidone—Asthenia—Prednisone—psoriasis	0.000136	0.00102	CcSEcCtD
Domperidone—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000136	0.00419	CbGpPWpGaD
Domperidone—Pruritus—Prednisone—psoriasis	0.000135	0.001	CcSEcCtD
Domperidone—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000133	0.00412	CbGpPWpGaD
Domperidone—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000133	0.00409	CbGpPWpGaD
Domperidone—KCNH2—SIDS Susceptibility Pathways—IL10—psoriasis	0.000131	0.00405	CbGpPWpGaD
Domperidone—Diarrhoea—Prednisone—psoriasis	0.00013	0.000969	CcSEcCtD
Domperidone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.00013	0.00401	CbGpPWpGaD
Domperidone—Nausea—Betamethasone—psoriasis	0.00013	0.000966	CcSEcCtD
Domperidone—Nausea—Dexamethasone—psoriasis	0.00013	0.000966	CcSEcCtD
Domperidone—Urticaria—Methotrexate—psoriasis	0.000126	0.00094	CcSEcCtD
Domperidone—Dizziness—Prednisone—psoriasis	0.000126	0.000936	CcSEcCtD
Domperidone—Abdominal pain—Methotrexate—psoriasis	0.000126	0.000935	CcSEcCtD
Domperidone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000124	0.00384	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000124	0.00383	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—IL13—psoriasis	0.000123	0.00381	CbGpPWpGaD
Domperidone—DRD2—GPCR ligand binding—HCAR2—psoriasis	0.000123	0.00379	CbGpPWpGaD
Domperidone—Vomiting—Prednisone—psoriasis	0.000121	0.0009	CcSEcCtD
Domperidone—Rash—Prednisone—psoriasis	0.00012	0.000893	CcSEcCtD
Domperidone—Dermatitis—Prednisone—psoriasis	0.00012	0.000892	CcSEcCtD
Domperidone—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—psoriasis	0.00012	0.0037	CbGpPWpGaD
Domperidone—Headache—Prednisone—psoriasis	0.000119	0.000887	CcSEcCtD
Domperidone—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000116	0.0036	CbGpPWpGaD
Domperidone—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000115	0.00355	CbGpPWpGaD
Domperidone—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000115	0.00354	CbGpPWpGaD
Domperidone—Asthenia—Methotrexate—psoriasis	0.000114	0.000849	CcSEcCtD
Domperidone—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000113	0.0035	CbGpPWpGaD
Domperidone—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000113	0.00349	CbGpPWpGaD
Domperidone—Nausea—Prednisone—psoriasis	0.000113	0.000841	CcSEcCtD
Domperidone—Pruritus—Methotrexate—psoriasis	0.000112	0.000837	CcSEcCtD
Domperidone—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00011	0.00338	CbGpPWpGaD
Domperidone—Diarrhoea—Methotrexate—psoriasis	0.000109	0.00081	CcSEcCtD
Domperidone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000109	0.00335	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000106	0.00326	CbGpPWpGaD
Domperidone—DRD2—G alpha (i) signalling events—CCL20—psoriasis	0.000105	0.00326	CbGpPWpGaD
Domperidone—Dizziness—Methotrexate—psoriasis	0.000105	0.000782	CcSEcCtD
Domperidone—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000103	0.00318	CbGpPWpGaD
Domperidone—Vomiting—Methotrexate—psoriasis	0.000101	0.000752	CcSEcCtD
Domperidone—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000101	0.0031	CbGpPWpGaD
Domperidone—Rash—Methotrexate—psoriasis	0.0001	0.000746	CcSEcCtD
Domperidone—Dermatitis—Methotrexate—psoriasis	0.0001	0.000745	CcSEcCtD
Domperidone—Headache—Methotrexate—psoriasis	9.96e-05	0.000741	CcSEcCtD
Domperidone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.59e-05	0.00296	CbGpPWpGaD
Domperidone—Nausea—Methotrexate—psoriasis	9.44e-05	0.000703	CcSEcCtD
Domperidone—DRD3—GPCR downstream signaling—HCAR2—psoriasis	9.08e-05	0.0028	CbGpPWpGaD
Domperidone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.99e-05	0.00277	CbGpPWpGaD
Domperidone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.87e-05	0.00274	CbGpPWpGaD
Domperidone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.66e-05	0.00267	CbGpPWpGaD
Domperidone—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.52e-05	0.00263	CbGpPWpGaD
Domperidone—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.39e-05	0.00259	CbGpPWpGaD
Domperidone—DRD3—GPCR ligand binding—CCL20—psoriasis	8.35e-05	0.00258	CbGpPWpGaD
Domperidone—DRD3—Signaling by GPCR—HCAR2—psoriasis	8.25e-05	0.00255	CbGpPWpGaD
Domperidone—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	7.93e-05	0.00245	CbGpPWpGaD
Domperidone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.76e-05	0.00239	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—IL10—psoriasis	7.71e-05	0.00238	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—IL4—psoriasis	7.5e-05	0.00232	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.34e-05	0.00226	CbGpPWpGaD
Domperidone—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.33e-05	0.00226	CbGpPWpGaD
Domperidone—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.18e-05	0.00222	CbGpPWpGaD
Domperidone—DRD2—GPCR downstream signaling—HCAR2—psoriasis	6.95e-05	0.00214	CbGpPWpGaD
Domperidone—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.83e-05	0.00211	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.8e-05	0.0021	CbGpPWpGaD
Domperidone—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.72e-05	0.00207	CbGpPWpGaD
Domperidone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.69e-05	0.00206	CbGpPWpGaD
Domperidone—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	6.67e-05	0.00206	CbGpPWpGaD
Domperidone—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.42e-05	0.00198	CbGpPWpGaD
Domperidone—DRD2—GPCR ligand binding—CCL20—psoriasis	6.39e-05	0.00197	CbGpPWpGaD
Domperidone—DRD3—Circadian rythm related genes—LEP—psoriasis	6.35e-05	0.00196	CbGpPWpGaD
Domperidone—DRD2—Signaling by GPCR—HCAR2—psoriasis	6.31e-05	0.00195	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.21e-05	0.00192	CbGpPWpGaD
Domperidone—DRD3—Circadian rythm related genes—NOS2—psoriasis	5.92e-05	0.00183	CbGpPWpGaD
Domperidone—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.83e-05	0.0018	CbGpPWpGaD
Domperidone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.58e-05	0.00172	CbGpPWpGaD
Domperidone—DRD3—Circadian rythm related genes—PPARG—psoriasis	5.53e-05	0.00171	CbGpPWpGaD
Domperidone—CYP3A7—Metabolism—NDUFA5—psoriasis	5.38e-05	0.00166	CbGpPWpGaD
Domperidone—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	5e-05	0.00154	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—HCAR2—psoriasis	4.87e-05	0.0015	CbGpPWpGaD
Domperidone—DRD2—Circadian rythm related genes—LEP—psoriasis	4.86e-05	0.0015	CbGpPWpGaD
Domperidone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.82e-05	0.00149	CbGpPWpGaD
Domperidone—DRD3—GPCR downstream signaling—CCL20—psoriasis	4.72e-05	0.00146	CbGpPWpGaD
Domperidone—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.64e-05	0.00143	CbGpPWpGaD
Domperidone—CYP3A7—Metabolism—CYP2S1—psoriasis	4.58e-05	0.00141	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—IFNG—psoriasis	4.54e-05	0.0014	CbGpPWpGaD
Domperidone—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.53e-05	0.0014	CbGpPWpGaD
Domperidone—DRD2—Circadian rythm related genes—NOS2—psoriasis	4.53e-05	0.0014	CbGpPWpGaD
Domperidone—DRD3—Signaling by GPCR—CCL20—psoriasis	4.28e-05	0.00132	CbGpPWpGaD
Domperidone—DRD2—Circadian rythm related genes—PPARG—psoriasis	4.23e-05	0.00131	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—TAGAP—psoriasis	4.22e-05	0.0013	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.22e-05	0.0013	CbGpPWpGaD
Domperidone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.22e-05	0.0013	CbGpPWpGaD
Domperidone—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	4.03e-05	0.00124	CbGpPWpGaD
Domperidone—CYP2B6—Metabolism—NDUFA5—psoriasis	3.98e-05	0.00123	CbGpPWpGaD
Domperidone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.96e-05	0.00122	CbGpPWpGaD
Domperidone—DRD3—Circadian rythm related genes—JUN—psoriasis	3.92e-05	0.00121	CbGpPWpGaD
Domperidone—CYP3A5—Metabolism—NDUFA5—psoriasis	3.89e-05	0.0012	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—HCAR2—psoriasis	3.73e-05	0.00115	CbGpPWpGaD
Domperidone—DRD3—G alpha (i) signalling events—CXCL8—psoriasis	3.72e-05	0.00115	CbGpPWpGaD
Domperidone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.61e-05	0.00111	CbGpPWpGaD
Domperidone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.61e-05	0.00111	CbGpPWpGaD
Domperidone—DRD2—GPCR downstream signaling—CCL20—psoriasis	3.61e-05	0.00111	CbGpPWpGaD
Domperidone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.47e-05	0.00107	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.43e-05	0.00106	CbGpPWpGaD
Domperidone—CYP2B6—Metabolism—CYP2S1—psoriasis	3.38e-05	0.00104	CbGpPWpGaD
Domperidone—CYP2C8—Metabolism—NDUFA5—psoriasis	3.37e-05	0.00104	CbGpPWpGaD
Domperidone—CYP3A5—Metabolism—CYP2S1—psoriasis	3.31e-05	0.00102	CbGpPWpGaD
Domperidone—DRD2—Signaling by GPCR—CCL20—psoriasis	3.28e-05	0.00101	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—TAGAP—psoriasis	3.23e-05	0.000997	CbGpPWpGaD
Domperidone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.14e-05	0.000969	CbGpPWpGaD
Domperidone—DRD2—Circadian rythm related genes—JUN—psoriasis	3e-05	0.000926	CbGpPWpGaD
Domperidone—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.96e-05	0.000913	CbGpPWpGaD
Domperidone—ABCB1—Allograft Rejection—TNF—psoriasis	2.94e-05	0.000906	CbGpPWpGaD
Domperidone—ABCB1—Metabolism—NDUFA5—psoriasis	2.94e-05	0.000906	CbGpPWpGaD
Domperidone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.92e-05	0.000901	CbGpPWpGaD
Domperidone—CYP2C8—Metabolism—CYP2S1—psoriasis	2.86e-05	0.000884	CbGpPWpGaD
Domperidone—DRD2—G alpha (i) signalling events—CXCL8—psoriasis	2.85e-05	0.000879	CbGpPWpGaD
Domperidone—CYP2D6—Metabolism—NDUFA5—psoriasis	2.77e-05	0.000854	CbGpPWpGaD
Domperidone—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.73e-05	0.000842	CbGpPWpGaD
Domperidone—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.6e-05	0.000803	CbGpPWpGaD
Domperidone—DRD3—Circadian rythm related genes—TP53—psoriasis	2.59e-05	0.000799	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—CCL20—psoriasis	2.53e-05	0.000781	CbGpPWpGaD
Domperidone—ABCB1—Metabolism—CYP2S1—psoriasis	2.5e-05	0.00077	CbGpPWpGaD
Domperidone—DRD3—Circadian rythm related genes—IL6—psoriasis	2.37e-05	0.000731	CbGpPWpGaD
Domperidone—CYP2D6—Metabolism—CYP2S1—psoriasis	2.35e-05	0.000726	CbGpPWpGaD
Domperidone—CYP1A2—Metabolism—NDUFA5—psoriasis	2.34e-05	0.000723	CbGpPWpGaD
Domperidone—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.26e-05	0.000699	CbGpPWpGaD
Domperidone—DRD3—GPCR ligand binding—CXCL8—psoriasis	2.25e-05	0.000696	CbGpPWpGaD
Domperidone—CYP3A7—Metabolism—CARM1—psoriasis	2.23e-05	0.00069	CbGpPWpGaD
Domperidone—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.18e-05	0.000674	CbGpPWpGaD
Domperidone—CYP1A2—Metabolism—CYP2S1—psoriasis	1.99e-05	0.000615	CbGpPWpGaD
Domperidone—DRD2—Circadian rythm related genes—TP53—psoriasis	1.98e-05	0.000611	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—CCL20—psoriasis	1.94e-05	0.000598	CbGpPWpGaD
Domperidone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.94e-05	0.000597	CbGpPWpGaD
Domperidone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.86e-05	0.000575	CbGpPWpGaD
Domperidone—DRD2—Circadian rythm related genes—IL6—psoriasis	1.81e-05	0.00056	CbGpPWpGaD
Domperidone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.81e-05	0.000558	CbGpPWpGaD
Domperidone—DRD2—GPCR ligand binding—CXCL8—psoriasis	1.72e-05	0.000532	CbGpPWpGaD
Domperidone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.69e-05	0.000522	CbGpPWpGaD
Domperidone—CYP2B6—Metabolism—CARM1—psoriasis	1.65e-05	0.00051	CbGpPWpGaD
Domperidone—CYP3A5—Metabolism—CARM1—psoriasis	1.62e-05	0.000498	CbGpPWpGaD
Domperidone—CYP3A4—Metabolism—CYP2S1—psoriasis	1.54e-05	0.000475	CbGpPWpGaD
Domperidone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.5e-05	0.000463	CbGpPWpGaD
Domperidone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.45e-05	0.000447	CbGpPWpGaD
Domperidone—CYP2C8—Metabolism—CARM1—psoriasis	1.4e-05	0.000432	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—SOCS1—psoriasis	1.39e-05	0.00043	CbGpPWpGaD
Domperidone—CYP3A7—Metabolism—CAT—psoriasis	1.37e-05	0.000424	CbGpPWpGaD
Domperidone—DRD3—Signaling by GPCR—TYK2—psoriasis	1.33e-05	0.00041	CbGpPWpGaD
Domperidone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.31e-05	0.000404	CbGpPWpGaD
Domperidone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.28e-05	0.000394	CbGpPWpGaD
Domperidone—DRD3—GPCR downstream signaling—CXCL8—psoriasis	1.27e-05	0.000393	CbGpPWpGaD
Domperidone—ABCB1—Metabolism—CARM1—psoriasis	1.22e-05	0.000376	CbGpPWpGaD
Domperidone—DRD3—Signaling by GPCR—CXCL8—psoriasis	1.16e-05	0.000357	CbGpPWpGaD
Domperidone—CYP2D6—Metabolism—CARM1—psoriasis	1.15e-05	0.000354	CbGpPWpGaD
Domperidone—CYP3A7—Metabolism—APOE—psoriasis	1.07e-05	0.00033	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—SOCS1—psoriasis	1.07e-05	0.000329	CbGpPWpGaD
Domperidone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.04e-05	0.000322	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—LEP—psoriasis	1.03e-05	0.000317	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—APOE—psoriasis	1.03e-05	0.000317	CbGpPWpGaD
Domperidone—DRD2—Signaling by GPCR—TYK2—psoriasis	1.02e-05	0.000314	CbGpPWpGaD
Domperidone—CYP2B6—Metabolism—CAT—psoriasis	1.02e-05	0.000314	CbGpPWpGaD
Domperidone—CYP3A5—Metabolism—CAT—psoriasis	9.93e-06	0.000307	CbGpPWpGaD
Domperidone—DRD2—GPCR downstream signaling—CXCL8—psoriasis	9.75e-06	0.000301	CbGpPWpGaD
Domperidone—CYP1A2—Metabolism—CARM1—psoriasis	9.73e-06	0.0003	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—NFKBIA—psoriasis	9.58e-06	0.000296	CbGpPWpGaD
Domperidone—CYP3A7—Metabolism—PPARG—psoriasis	9.3e-06	0.000287	CbGpPWpGaD
Domperidone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.09e-06	0.000281	CbGpPWpGaD
Domperidone—DRD2—Signaling by GPCR—CXCL8—psoriasis	8.85e-06	0.000273	CbGpPWpGaD
Domperidone—CYP2C8—Metabolism—CAT—psoriasis	8.6e-06	0.000266	CbGpPWpGaD
Domperidone—CYP2B6—Metabolism—APOE—psoriasis	7.9e-06	0.000244	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—LEP—psoriasis	7.87e-06	0.000243	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—APOE—psoriasis	7.87e-06	0.000243	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—TYK2—psoriasis	7.85e-06	0.000242	CbGpPWpGaD
Domperidone—CYP3A5—Metabolism—APOE—psoriasis	7.72e-06	0.000238	CbGpPWpGaD
Domperidone—CYP3A4—Metabolism—CARM1—psoriasis	7.51e-06	0.000232	CbGpPWpGaD
Domperidone—ABCB1—Metabolism—CAT—psoriasis	7.5e-06	0.000231	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—NFKBIA—psoriasis	7.33e-06	0.000226	CbGpPWpGaD
Domperidone—CYP2D6—Metabolism—CAT—psoriasis	7.06e-06	0.000218	CbGpPWpGaD
Domperidone—CYP2B6—Metabolism—PPARG—psoriasis	6.88e-06	0.000212	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—CXCL8—psoriasis	6.83e-06	0.000211	CbGpPWpGaD
Domperidone—CYP3A5—Metabolism—PPARG—psoriasis	6.72e-06	0.000208	CbGpPWpGaD
Domperidone—CYP2C8—Metabolism—APOE—psoriasis	6.69e-06	0.000206	CbGpPWpGaD
Domperidone—DRD3—Signaling by GPCR—IL6—psoriasis	6.5e-06	0.000201	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—JUN—psoriasis	6.35e-06	0.000196	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—NFKB1—psoriasis	6.11e-06	0.000189	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—TYK2—psoriasis	6.01e-06	0.000185	CbGpPWpGaD
Domperidone—CYP1A2—Metabolism—CAT—psoriasis	5.98e-06	0.000185	CbGpPWpGaD
Domperidone—ABCB1—Metabolism—APOE—psoriasis	5.82e-06	0.00018	CbGpPWpGaD
Domperidone—CYP2C8—Metabolism—PPARG—psoriasis	5.82e-06	0.00018	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—VEGFA—psoriasis	5.55e-06	0.000171	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—STAT3—psoriasis	5.5e-06	0.00017	CbGpPWpGaD
Domperidone—CYP2D6—Metabolism—APOE—psoriasis	5.49e-06	0.000169	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—CXCL8—psoriasis	5.23e-06	0.000161	CbGpPWpGaD
Domperidone—ABCB1—Metabolism—PPARG—psoriasis	5.07e-06	0.000157	CbGpPWpGaD
Domperidone—DRD2—Signaling by GPCR—IL6—psoriasis	4.97e-06	0.000153	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—JUN—psoriasis	4.86e-06	0.00015	CbGpPWpGaD
Domperidone—CYP2D6—Metabolism—PPARG—psoriasis	4.78e-06	0.000148	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—NFKB1—psoriasis	4.68e-06	0.000144	CbGpPWpGaD
Domperidone—CYP1A2—Metabolism—APOE—psoriasis	4.65e-06	0.000144	CbGpPWpGaD
Domperidone—CYP3A4—Metabolism—CAT—psoriasis	4.62e-06	0.000143	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—VEGFA—psoriasis	4.25e-06	0.000131	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—STAT3—psoriasis	4.2e-06	0.00013	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—TP53—psoriasis	4.19e-06	0.000129	CbGpPWpGaD
Domperidone—CYP1A2—Metabolism—PPARG—psoriasis	4.05e-06	0.000125	CbGpPWpGaD
Domperidone—DRD3—Signaling Pathways—IL6—psoriasis	3.84e-06	0.000118	CbGpPWpGaD
Domperidone—CYP3A4—Metabolism—APOE—psoriasis	3.59e-06	0.000111	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—TP53—psoriasis	3.21e-06	9.9e-05	CbGpPWpGaD
Domperidone—CYP3A4—Metabolism—PPARG—psoriasis	3.13e-06	9.65e-05	CbGpPWpGaD
Domperidone—DRD2—Signaling Pathways—IL6—psoriasis	2.94e-06	9.06e-05	CbGpPWpGaD
